Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phenomix Folds After Diabetes Drug Fails To Attract Partner To Fill Forest's Shoes

This article was originally published in The Pink Sheet Daily

Executive Summary

DPP-4 drug dutogliptin was a casualty of the highly competitive, regulated and expensive space for diabetes drug development.

You may also be interested in...



No Obvious Prescription For Biopharma Investors

In our second annual Life Science VC Survey, biopharma investors continue to look to oncology and rare disease, while their cold shoulder toward metabolic disease seems to be warming. Even though most agree the traditional biotech funding model is broken, our participants are far from convinced that new models such as asset-based financing are the answer.

Diabetes Drug Development: Seeing Light In The Dark Ages?

Tougher regulatory hurdles introduced three years ago extended the timelines for successful diabetes drug development, discouragiing investment and partnering activity. An ever-increasing incidence of diabetes, metabolic disorders, and obesity continues to drive innovation and the development of new medicines – but with less emphasis on novel mechanisms.

Phase4 Spins Out Of Nomura To Focus On Europe

When the management team at Phase4 Ventures in February 2011 spun the venture capital business out of parent Nomura, the move highlighted two important features of the VC landscape. The first is continued investor interest in Europe, which will replace the US as Phase4's primary geographic focus, and the second is the growing, and increasingly creative, role for large secondary players in the still-vulnerable VC sector.

Related Content

Topics

UsernamePublicRestriction

Register

PS071113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel